DBV Technologies to Join Guggenheim Biotech Summit

DBV Technologies, a late-stage biopharmaceutical company, will participate in the Guggenheim Securities Emerging Outlook: Biotech Summit. The event is scheduled for February 11-12, 2026, in New York. Daniel Tassé, the company's CEO, will lead a fireside chat on February 12 at 2:30 p.m. ET. The discussion will be streamed live and later available for 90 days on DBV Technologies’ website.

Based in Châtillon, France, DBV Technologies focuses on developing treatments for food allergies using its VIASKIN® patch technology. This non-invasive method introduces allergens to the immune system through the skin. The company aims to address significant unmet medical needs, especially in young children with peanut allergies.